Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced it will release its second quarter 2024 financial and operational results on Thursday, August 1, 2024, before markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240719692619/en/
Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.